Eli Lilly and Company has significantly bolstered its position in the rapidly evolving cell and gene therapy (CGT) landscape with the announcement of its agreement to acquire Kelonia Therapeutics, a pioneering developer of in vivo gene therapy platforms. The deal, valued at up to $7 billion, represents Eli Lilly’s second major strategic move into the in vivo gene therapy space this year, underscoring its commitment to unlocking the full potential of this transformative therapeutic modality. This acquisition, comprising a $3.25 billion upfront cash payment and up to $3.75 billion in potential milestone payments, grants Lilly access to Kelonia’s advanced lentiviral-based in vivo gene therapy platform, known as iGPS, along with its promising pipeline of oncology assets.
The iGPS platform is engineered to enable the body’s own immune cells to autonomously generate therapeutic chimeric antigen receptor T-cells (CAR-Ts). This innovative approach aims to overcome the significant manufacturing complexities, safety concerns, and accessibility challenges historically associated with traditional autologous CAR-T therapies, which require extensive ex vivo manipulation of a patient’s own cells. By shifting the CAR-T production process to an in vivo setting, Lilly anticipates a more streamlined, cost-effective, and broadly applicable treatment paradigm.
At the heart of the acquisition lies Kelonia’s lead candidate, KLN-1010. This single-dose, in vivo therapy is specifically designed to target the B-cell maturation antigen (BCMA), a key driver in multiple myeloma. KLN-1010 is currently undergoing evaluation in a Phase I clinical trial, dubbed the inMMyCAR trial (NCT07075185), for patients with refractory multiple myeloma. The early clinical data emerging from this trial are reportedly highly encouraging, according to Jacob Van Naarden, Executive Vice President and President of Lilly Oncology. "The early clinical data for KLN-1010 are highly encouraging, both as a potential step forward for patients with multiple myeloma and as proof of concept for Kelonia’s platform," Van Naarden stated, highlighting the dual significance of the asset.
Beyond KLN-1010, Kelonia’s pipeline includes a preclinical bispecific CAR-T therapy targeting both BCMA and CD19, as well as an earlier-stage discovery program with an undisclosed mechanism of action. The integration of these assets into Eli Lilly’s portfolio is expected to accelerate the development and potential commercialization of novel treatments for a range of hematological malignancies.
A Strategic Expansion into In Vivo Gene Therapy
Eli Lilly’s acquisition of Kelonia Therapeutics follows closely on the heels of its February 2026 acquisition of Orna Therapeutics, a deal valued at $2.4 billion. Orna Therapeutics is also a leader in the in vivo gene therapy space, focusing on a lipid nanoparticle (LNP)-based platform that utilizes transient expression systems. This dual investment strategy demonstrates Lilly’s intent to establish a comprehensive in vivo gene therapy capability, encompassing both lentiviral and LNP-based delivery systems.
Jack Cuthbertson, a senior oncology analyst at GlobalData, commented on Lilly’s strategic approach, stating, "Lilly’s Kelonia buyout could be a sign of the Indiana-based pharma covering all bases following its $2.4bn acquisition of Orna Therapeutics in February 2026. There are currently two major types of in vivo CAR-T technologies: lipid nanoparticles (LNPs) loaded with transient expression systems as used by Orna, and lentiviral vectors with stable expression systems employed by Kelonia." This diversification allows Lilly to explore the distinct advantages and potential synergies of each technological approach, positioning it to capitalize on the most promising advancements in the field.
Understanding the In Vivo Landscape: LNP vs. Lentiviral Vectors
The burgeoning field of in vivo gene therapy offers a compelling alternative to traditional ex vivo cell therapies, promising to streamline manufacturing, reduce costs, and enhance patient access. Within this space, the two primary technological avenues are LNP-based delivery and lentiviral vector-based delivery.
LNP-based systems, exemplified by Orna Therapeutics’ approach, typically involve encapsulating genetic material within lipid nanoparticles. These nanoparticles are designed to transiently express the therapeutic payload within target cells. While often associated with greater tolerability, LNP-based systems may face challenges in achieving the sustained, complete responses that have been observed with ex vivo CAR-T therapies.
Lentiviral vector-based systems, as pioneered by Kelonia Therapeutics, utilize modified lentiviruses to deliver genetic material that integrates stably into the host cell genome. This stable integration can lead to prolonged expression of the therapeutic protein, potentially offering more durable responses. However, lentiviral vectors have historically raised some safety concerns, particularly regarding the potential for immune responses when high doses are administered to achieve therapeutic effects.
Navigating Safety and Efficacy: A Data-Driven Perspective
The comparative efficacy and safety profiles of LNP- and lentiviral-based in vivo gene therapies remain a critical area of ongoing research and development. Cuthbertson noted that while early data suggest lentiviral systems can achieve complete responses with favorable prognoses, safety considerations are paramount. "A lot of the early data shows that lentiviral systems can effectively deliver complete responses with good prognoses. However, there are some safety concerns around immune responses when high lentiviral doses are given to deliver a therapeutic effect," he explained.
This caution is underscored by recent clinical trial data. For instance, a Phase I readout from AstraZeneca’s lentiviral in vivo CAR-T therapy identified safety signals that GlobalData analysts have described as "concerning." In a small cohort of five patients, all participants experienced adverse events graded as Grade 3 or above. The study authors subsequently recommended stricter risk stratification protocols for future in vivo CAR-T trials. Such findings highlight the critical need for rigorous safety monitoring and risk management as these novel therapies advance through clinical development.
Conversely, LNP-based alternatives are generally perceived as more tolerable. However, the challenge lies in ensuring these platforms can elicit sustained therapeutic effects comparable to existing cell therapies. The optimal delivery system and integration strategy for in vivo gene therapies will likely be determined by a combination of the specific therapeutic target, the disease indication, and the balance between efficacy and safety.
The Broader Implications for Cell and Gene Therapy
The acquisition of Kelonia Therapeutics by Eli Lilly is emblematic of a broader industry trend towards consolidation and strategic investment in the CGT sector. As in vivo therapies gain traction, they are increasingly viewed as a potential solution to the high cost and intricate manufacturing processes associated with cell and gene therapies, thereby lowering barriers to global access. The ability to administer a therapy in a single, in vivo infusion, rather than requiring complex ex vivo cell processing and subsequent reinfusion, could revolutionize patient care and expand the reach of these powerful treatments.
Industry experts have consistently emphasized the importance of developing robust commercial strategies early in the lifecycle of CGT products. At the 2026 Advanced Therapies conference in London, investors highlighted the critical need for foresight in navigating the "biotech valley of death" and establishing clear pathways to market for these innovative therapies. Eli Lilly’s proactive approach, by securing multiple advanced in vivo platforms, suggests a long-term vision for dominating this emerging therapeutic frontier.
The technical and logistical challenges associated with scaling up in vivo therapies for commercial viability remain a significant consideration. As these therapies progress from the clinic to broader patient populations, developers must address issues related to manufacturing capacity, distribution, and regulatory pathways. Lilly’s acquisition of Kelonia not only brings cutting-edge technology but also a pipeline of assets that can serve as proof points for the platform’s potential.
The strategic move by Eli Lilly to acquire Kelonia Therapeutics, building upon its earlier investment in Orna Therapeutics, signifies a profound commitment to the in vivo gene therapy revolution. By embracing both lentiviral and LNP-based delivery systems, Lilly is strategically positioning itself to navigate the complexities of this rapidly advancing field and potentially deliver life-changing therapies to a wider range of patients worldwide. The success of KLN-1010 and Kelonia’s broader pipeline will be closely watched as indicators of the future direction and impact of in vivo gene therapy.
Leave a Reply